Alzheimer's Disease Clinical Trials

35 studies are recruiting for alzheimer's disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

   Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn wh…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT04396873 on ClinicalTrials.gov

2. PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

   Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflam…

   Stage

   Phase 1

   Ages

   50 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT07169630 on ClinicalTrials.gov

3. A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

   Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may pro…

   Stage

   Phase 1

   Ages

   50 to 90

   Site

   Irvine Center for Clinical Research /ID# 277752, Irvine, California

   Locations

   13 in total

   Run by

   AbbVie

   See if you can join NCT07599670 on ClinicalTrials.gov

4. Pulsed Electromagnetic Field Treatment With Dementia Patients

   An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over…

   Stage

   Not phased

   Ages

   50 to 100

   Site

   University of Miami, Boca Raton, Florida

   Run by

   Herrick Medical LLC

   See if you can join NCT06862557 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

   Stage

   Phase 3

   Ages

   60 to 85

   Site

   Fullerton Neurology and Headache Center, Fullerton, California

   Locations

   127 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06976203 on ClinicalTrials.gov

6. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Chandler Clinical Trials, LLC, Chandler, Arizona

   Locations

   144 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011745 on ClinicalTrials.gov

7. A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease

   The primary purpose of this study is to evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemo…

   Stage

   Not phased

   Ages

   Any age

   Site

   Eisai Trial Site #1, Nutley, New Jersey

   Run by

   Eisai Inc.

   See if you can join NCT07821658 on ClinicalTrials.gov

8. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

   This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

   Stage

   Phase 3

   Ages

   55 to 80

   Site

   Irvine Center for Clinical Research, Irvine, California

   Locations

   7 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07717411 on ClinicalTrials.gov

9. Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

   To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide …

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   University of Pennsylvania

   See if you can join NCT05658913 on ClinicalTrials.gov

10. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

    VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

    Stage

    Phase 1

    Ages

    30 to 80

    Site

    K2 Medical Research, LLC, Maitland, Florida

    Run by

    Voyager Therapeutics

    See if you can join NCT07764146 on ClinicalTrials.gov

11. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    Stage

    Phase 3

    Ages

    60 to 85

    Site

    Healthy Brain Clinic, Long Beach, California

    Locations

    119 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06976216 on ClinicalTrials.gov

12. Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music

    This study examines whether Clinically Designed Improvisatory Music (CDIM) can reduce anxiety in people living with Alzheimer's disease and anxiety (AD-A), and whether it can also lessen caregiver burden. CDIM is a live, receptive music-based intervention that uses slow tempi, simple diatonic melod…

    Stage

    Not phased

    Ages

    55 and older

    Site

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07775625 on ClinicalTrials.gov

13. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive …

    Stage

    Phase 2

    Ages

    55 to 85

    Site

    Charter Research - Lady Lake- Site Number : 8400004, The Villages, Florida

    Run by

    Sanofi

    See if you can join NCT07688213 on ClinicalTrials.gov

14. Dominantly Inherited Alzheimer Network (DIAN)

    The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic Jacksonville, Jacksonville, Florida

    Locations

    26 in total

    Run by

    Washington University School of Medicine

    See if you can join NCT00869817 on ClinicalTrials.gov

15. Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

    This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

    Stage

    Not phased

    Ages

    40 to 90

    Site

    Insigth Hospital and Medical Center Chicago, Chicago, Illinois

    Locations

    5 in total

    Run by

    Neurogen Biomarking LLC

    See if you can join NCT07701161 on ClinicalTrials.gov

16. A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

    Stage

    Phase 1

    Ages

    35 to 85

    Site

    K2 Medical Research The Villages LLC, Lady Lake, Florida

    Locations

    26 in total

    Run by

    AC Immune SA

    See if you can join NCT05462106 on ClinicalTrials.gov

17. Low-Dose Radiotherapy for Alzheimer's Disease

    To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with …

    Stage

    Phase 1

    Ages

    50 and older

    Site

    Renaissance Institute of Precision Oncology & Radiosurgery, Winter Park, Florida

    Run by

    Evan Thomas

    See if you can join NCT07693140 on ClinicalTrials.gov

18. A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

    This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

    Stage

    Phase 2

    Ages

    50 to 85

    Site

    Banner Alzheimers Institute, Phoenix, Arizona

    Locations

    74 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07094516 on ClinicalTrials.gov

19. NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE

    The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach. The main questions it …

    Stage

    Not phased

    Ages

    55 to 90

    Site

    Baylor College of Medicine, Houston, Texas

    Run by

    Chi-Ying (Roy) Lin

    See if you can join NCT07667478 on ClinicalTrials.gov

20. Crownlands Observing Progression With Neurons Study

    The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The primary objective is to identify the molecular and genetic modules that differentiate patient subtypes and predict progression of AD. Participants will …

    Stage

    Not phased

    Ages

    55 and older

    Site

    Capital Neurology, Germantown, Maryland

    Run by

    Crownlands

    See if you can join NCT07611396 on ClinicalTrials.gov

21. TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

    The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also …

    Stage

    Phase 1

    Ages

    60 and older

    Site

    Shiley Marcos Alzheimer's Disease Center, San Diego, California

    Run by

    University of California, San Diego

    See if you can join NCT06548191 on ClinicalTrials.gov

22. Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

    The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of cancer, …

    Stage

    Phase 2

    Ages

    50 and older

    Site

    Weill Cornell Medicine Brain Health Imaging Institute, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT07553338 on ClinicalTrials.gov

23. A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

    The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Eisai Trial Site #1, Nutley, New Jersey

    Run by

    Eisai Korea Inc.

    See if you can join NCT06810960 on ClinicalTrials.gov

24. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

    Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful rel…

    Stage

    Not phased

    Ages

    60 to 90

    Site

    JEM Research Institute, Atlantis, Florida

    Locations

    26 in total

    Run by

    GAP Innovations, PBC

    See if you can join NCT06584357 on ClinicalTrials.gov

25. Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

    Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only re…

    Stage

    Not phased

    Ages

    65 to 100

    Site

    Massachusetts Institute of Technology, Cambridge, Massachusetts

    Run by

    Massachusetts Institute of Technology

    See if you can join NCT05655195 on ClinicalTrials.gov